Inventiva S.A.
IVA
Classement en actions
#10620
Inventiva S.A. is a biopharmaceutical firm currently in the clinical... Inventiva S.A. is a biopharmaceutical firm currently in the clinical development phase, specializing in creating orally administered small molecule treatments for conditions such as non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS), and various other ailments. Their primary drug candidate, Lanifibranor, has successfully concluded Phase IIb clinical trials for the management of NASH. Furthermore, the company is advancing Odiparcil, a compound that has finished Phase IIa clinical testing specifically for treating the MPS VI subtype. Beyond these, Inventiva maintains a development pipeline featuring several early-stage projects targeting oncology and other medical conditions. Strategic partnerships are in place with AbbVie to address autoimmune diseases, and with Boehringer Ingelheim International GmbH for innovating therapies for idiopathic pulmonary fibrosis. Established in 2011, Inventiva S.A. operates from its headquarters in Daix, France.
Prix de l'action
$3.24
Capitalisation boursière
$764.93M
Changement (1 jour)
-0.18%
Changement (1 an)
-19.27%
Pays
FR
Échange Inventiva S.A. (IVA)
Catégorie
Healthcare
Capitalisation boursière de Inventiva S.A.(IVA)
Capitalisation boursière: $764.93M
En October 2026, Inventiva S.A. a une capitalisation boursière de $764.93M. Cela fait de Inventiva S.A. la 10620th entreprise la plus valorisée au monde selon nos données. La capitalisation boursière, souvent appelée market cap, correspond à la valeur totale des actions en circulation d’une entreprise cotée en bourse, et est couramment utilisée pour évaluer sa valeur.
Historique de la capitalisation boursière de Inventiva S.A. du 2021 au 2026
IVA par rapport au top 5 des plus populaires stocks
| Prix pour IVA | L’actif B | La capitalisation boursière de B | Résultats | |
|---|---|---|---|---|
$37,627.95
$445.36M
|
$5.233T | +1,174,812.01% | ||
|
$35,972.96
$445.36M
|
$5.002T | +1,123,135.85% | ||
|
$29,916.28
$445.36M
|
$4.160T | +934,019.13% | ||
|
$28,503.15
$445.36M
|
$3.964T | +889,894.92% | ||
|
$20,356.18
$445.36M
|
$2.831T | +635,510.40% |
